Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STEM PACE
ISRCTN47877138Phase 2Completed
- Sponsor
- Heidelberg University
- Start
- May 2013
- Modality
- Small Molecules, Peptides, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of allogeneic peripheral blood progenitor cells, fludarabine, cyclophosphamide, cyclosporine and mycophenolate mofetil in pancreatic cancer (PC) and pancreatic adenocarcinoma (PDAC), sponsored by Heidelberg University. Primary endpoint: 2-year progression-free survival from registration. Started May 2013; status: completed.
02
Drugs
allogeneic peripheral blood progenitor cellsfludarabinecyclophosphamidecyclosporinemycophenolate mofetil
03
Conditions
pancreatic cancer (PC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ISRCTN47877138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN47877138.